Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jun 28;18(1):289.
doi: 10.1186/s12879-018-3195-5.

Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis

Xi Li  1   2 , Yongbo Huang  1   2 , Zhiheng Xu  1   2 , Rong Zhang  1   2 , Xiaoqing Liu  1   2 , Yimin Li  3   4 , Pu Mao  5   6
Affiliations
Meta-Analysis

Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis

Xi Li et al. BMC Infect Dis. .

Abstract

Background: Cytomegalovirus (CMV) infection is common in immunocompetent patients in intensive care units (ICUs). However, whether CMV infection or CMV reactivation contributes to mortality of immunocompetent patients remains unclear.

Methods: A literature search was conducted for relevant studies published before May 30, 2016. Studies reporting on CMV infection in immunocompetent patients in ICUs and containing 2 × 2 tables on CMV results and all-cause mortality were included.

Results: Eighteen studies involving 2398 immunocompetent patients admitted to ICUs were included in the meta-analysis. The overall rate of CMV infection was 27% (95%CI 22-34%, I2 = 89%, n = 2398) and the CMV reactivation was 31% (95%CI 24-39%, I2 = 74%, n = 666). The odds ratio (OR) for all-cause mortality among patients with CMV infection, compared with those without infection, was 2.16 (95%CI 1.70-2.74, I2 = 10%, n = 2239). Moreover, upon exclusion of studies in which antiviral treatment was possibly or definitely provided to some patients, the association of mortality rate with CMV infection was also statistically significant (OR: 1.69, 95%CI 1.01-2.83, I2 = 37%, n = 912,). For CMV seropositive patients, the OR for mortality in patients with CMV reactivation as compared with patients without CMV reactivation was 1.72 (95%CI 1.04-2.85, I2 = 29%, n = 664). Patients with CMV infection required significantly longer mechanical ventilation (mean difference (MD): 9 days (95% CI 5-14, I2 = 81%, n = 875)) and longer duration of ICU stay (MD: 12 days (95% CI 7-17, I2 = 70%, n = 949)) than patients without CMV infection. When analysis was limited to detection in blood, CMV infection without antiviral drug treatment or reactivation was not significantly associated with higher mortality (OR: 1.69, 95%CI 0.81-3.54, I2 = 52%, n = 722; OR: 1.49, I2 = 63%, n = 469).

Conclusion: Critically ill patients without immunosuppression admitted to ICUs show a high rate of CMV infection. CMV infection during the natural unaltered course or reactivation in critically ill patients is associated with increased mortality, but have no effect on mortality when CMV in blood. More studies are needed to clarify the impact of CMV infection on clinical outcomes in those patients.

Keywords: Cytomegalovirus; Immunocompetent; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This review evaluated data from published studies and was exempt from ethics committee approval. This review did not involve any direct research on patients, and no informed consent was required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow of information through the different phases of a systematic review
Fig. 2
Fig. 2
Overall detection rate of CMV
Fig. 3
Fig. 3
The effect of CMV infection on all-cause mortality in all trials(a), in patients without antiviral therapy(b)
Fig. 4
Fig. 4
The mean difference in mechanical ventilation days in all trials (a) and the length of ICU stay in all trials (b) between active and non-CMV infection
Fig. 5
Fig. 5
The rate of CMV seropositivity(a) and reactivation(b) and the forest plot displaying the effect of CMV reactivation on mortality in all trials(c)
See this image and copyright information in PMC

References

    1. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Investig. 2011;121(5):1673–1680. doi: 10.1172/JCI45449. - DOI - PMC - PubMed
    1. Stadler LP, Bernstein DI, Callahan ST, Ferreira J, Gorgone Simone GA, Edwards KM, Stanberry LR, Rosenthal SL. Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin Infect Dis. 2010;51(10):e76–e81. doi: 10.1086/656918. - DOI - PMC - PubMed
    1. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol. 2010;20(5):311–326. doi: 10.1002/rmv.659. - DOI - PubMed
    1. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50(11):1439–1447. doi: 10.1086/652438. - DOI - PMC - PubMed
    1. Musiani M, Zerbini M, Zauli D, Cometti G, La Placa M. Impairment of cytomegalovirus and host balance in elderly subjects. J Clin Pathol. 1988;41(7):722–725. doi: 10.1136/jcp.41.7.722. - DOI - PMC - PubMed

Substances